Overview
GRI market data
Price History
No market bars yet for GRI. This page will populate once the next provider sweep lands.
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for GRI. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — GRI Bio, Inc. (GRI)SEC EDGAR · Jun 18, 2026, 8:50 PM
GRI Bio Says FDA Grants Orphan Drug Designation To GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis, Irreversible And Ultimately Fatal Lung DiseaseBenzinga · Jun 18, 2026, 12:40 PM
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should KnowBenzinga · Jun 1, 2026, 12:43 PM
Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $32Benzinga · Jun 1, 2026, 10:28 AM
GRI Bio Q1 EPS $(1.61) Misses $(0.91) EstimateBenzinga · May 14, 2026, 12:45 PM
GRI Bio Says Growing Body Of Phase 2a Clinical, Translational And Biomarker Data Continues To Reinforce GRI-0621's Differentiated Therapeutic Potential In Idiopathic Pulmonary FibrosisBenzinga · May 14, 2026, 12:41 PM